Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Francesca Bruce

Francesca Bruce has been writing news and analysis about all things affecting the pharmaceutical industry since 2008. She has paid special attention to policy and regulatory developments but particularly likes to write about market access and how medicines may  - or may not  -  make it to patients. She generally writes about Europe, but really enjoys uncovering news from further corners of the globe, especially Latin America and the Middle East.

Latest From Francesca Bruce

England Unveils £680m Innovative Medicines Fund

England’s Innovative Medicines Fund is aimed at providing earlier access to promising new treatments, including gene therapies, when further data is needed for routine commissioning.

Europe United Kingdom

England: HTA Body’s Income Hit By COVID-19

England’s health technology assessment body NICE did not recover costs for technology appraisals through fees thanks to the COVID-19 pandemic.

Europe United Kingdom

Vertex Inks New Cystic Fibrosis Deals In Europe

Reimbursement timelines in Italy and France for the treatments in question have been quicker than the average.

Europe Respiratory

International Horizon Scanning Initiative Moves Forward

An initiative that will improve payers’ ability to negotiate prices for disruptive new drugs is closer to fruition.

Europe Innovation

Environmental Criteria in Medicines Tendering Set To Increase

Environmental criteria in tendering could lead to short term cost increases but long-term savings for pharmaceutical companies.

Europe Denmark

UK MHRA Awards Bluebird’s LentiGlobin An Innovation Passport

Companies that are in earlier stages of the drug development process will benefit most from the UK regulator's new pathway for innovative medicines.

Europe United Kingdom
See All
UsernamePublicRestriction

Register